Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001172661-24-004709
Filing Date
2024-11-13
Accepted
2024-11-13 18:00:27
Documents
1

Document Format Files

Seq Description Document Type Size
1 polar-cldx093024a1.htm SC 13G/A 86352
  Complete submission text file 0001172661-24-004709.txt   88114
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Subject) CIK: 0000744218 (see all company filings)

EIN.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-37761 | Film No.: 241456004
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)

Mailing Address 16 PALACE STREET LONDON X0 SW1E 5JD
Business Address 16 PALACE STREET LONDON X0 SW1E 5JD 02072272700
Polar Capital Holdings Plc (Filed by) CIK: 0001837309 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 0331
Type: SC 13G/A